# VIBERZI — FDA application NDA206940

Informational only - not investment advice.

Application NDA206940 · type NDA · FDA status: approved · original approval 2015-05-27

Listed sponsor: ABBVIE · [ABBV company profile](/company/ABBV/) · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

## FDA application facts

| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 001 | VIBERZI | ELUXADOLINE | TABLET | ORAL | 75MG | Prescription | not listed | Yes |
| 002 | VIBERZI | ELUXADOLINE | TABLET | ORAL | 100MG | Prescription | not listed | Yes |

## Orange Book patent and exclusivity listings

- Patent 8691860, product 001; listed patent expiry date: 2028-07-07.
- Patent 8691860, product 002; listed patent expiry date: 2028-07-07.
- Patent 9115091, product 001; listed patent expiry date: 2028-07-07.
- Patent 9115091, product 002; listed patent expiry date: 2028-07-07.
- Patent 9364489, product 001; listed patent expiry date: 2028-07-07.
- Patent 9364489, product 002; listed patent expiry date: 2028-07-07.
- Patent 9789125, product 001; listed patent expiry date: 2028-07-07.
- Patent 9789125, product 001; listed patent expiry date: 2028-07-07.
- Patent 9789125, product 002; listed patent expiry date: 2028-07-07.
- Patent 9789125, product 002; listed patent expiry date: 2028-07-07.
- Patent 7741356, product 001; listed patent expiry date: 2029-05-27.
- Patent 7741356, product 002; listed patent expiry date: 2029-05-27.
- Patent 10188632, product 001; listed patent expiry date: 2033-03-14.
- Patent 10188632, product 002; listed patent expiry date: 2033-03-14.
- Patent 11007179, product 001; listed patent expiry date: 2033-03-14.
- Patent 11007179, product 002; listed patent expiry date: 2033-03-14.
- Patent 11090291, product 001; listed patent expiry date: 2033-03-14.
- Patent 11090291, product 002; listed patent expiry date: 2033-03-14.
- Patent 11160792, product 001; listed patent expiry date: 2033-03-14.
- Patent 11160792, product 002; listed patent expiry date: 2033-03-14.
- Patent 11229627, product 001; listed patent expiry date: 2033-03-14.
- Patent 11229627, product 002; listed patent expiry date: 2033-03-14.
- Patent 11311516, product 001; listed patent expiry date: 2033-03-14.
- Patent 11311516, product 002; listed patent expiry date: 2033-03-14.
- Patent 11484527, product 002; listed patent expiry date: 2033-03-14.
- Patent 12097187, product 001; listed patent expiry date: 2033-03-14.
- Patent 9675587, product 001; listed patent expiry date: 2033-03-14.
- Patent 9675587, product 002; listed patent expiry date: 2033-03-14.

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

## Compound cross-links

- ELUXADOLINE · UNII 45TPJ4MBQ1 · [lmmol compound QFNHIDANIVGXPE-FNZWTVRRSA-N](https://lmmol.com/compound/QFNHIDANIVGXPE-FNZWTVRRSA-N)

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

## Related pages

- [Sponsor company](/company/ABBV/)
- [FDA-approved application index](/drug/)
- [Large-cap biopharma](/compare/pharma/)

Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files · https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files · https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206940. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.